Rare Biomarkers Specimen Collection And Stabilization Market - Databook 2025 to 2034

The global rare biomarkers specimen collection and stabilization market size was estimated at USD 41,990 million in 2024 and is projected to be worth around USD 1,62,630 million by 2034, growing at a CAGR of 14.5% from 2025 to 2034.

Highlights of the Rare Biomarkers Specimen Collection And Stabilization Market

• North America dominated the global rare biomarkers specimen collection and stabilization market in 2024.
• Asia Pacific is anticipated to grow at the fastest rate during the forecast period.
• By biomarker, the circulating cell-free DNA (ccfDNA) segment underwent notable growth in the rare biomarkers specimen collection and stabilization market during 2024.
• By biomarker, the circulating cell-free RNA (ccfRNA)/ miRNA segment is predicted to witness significant growth in the market over the forecast period.
• By end use, the research segment captured a significant portion of the rare biomarkers specimen collection and stabilization market in 2024.
• By end use, the diagnostics segment is projected to expand rapidly in the market over the forecast period.

Industry Valuation and Growth Rate Projection

The rare biomarkers specimen collection and stabilization market refers to the collection and preservation of biological samples containing rare or low-abundance molecules that act as indications of specific biological processes, situations, or diseases. A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process or a condition, or a disease.

The rising prevalence of chronic conditions leads to the need for early detection. According to a report published in March 2025, the global burden and biomarkers of cardiovascular disease attributable to ambient particulate matter pollution (APMP).

• According to a report published in July 2024, around 400000 people died due to cardiovascular problems in Brazil in 2022.

Rare Biomarkers Specimen Collection And Stabilization Market: Stats and Figures

According to a report published in June 2024, cardiovascular diseases among Indian Older Adults are notable. In India, CVDs are the leading cause of death and disability and accounted for 31.8% of all deaths and 14.7% disability adjusted life years (DALYs) globally in the year 2017. In India, key risk factors for CVDs include sedentary lifestyle, diabetes, poor diet, obesity, hypertension (HT), and high cholesterol.

According to a report published on cardiovascular health and disease in China in 2022, the number of current CVD patients in China is estimated to be approximately 330 million, including 245 million hypertension cases, 43.5 million peripheral artery disease cases, 2 million congenital heart disease cases, 2.5 million rheumatic heart disease cases, 13 million stroke cases, and 11.39 million coronary heart disease cases.

How AI Benefitted the Market

• Artificial intelligence (AI) has the potential to play a significant and challenging role through the development of machine learning (ML) algorithms that can analyze a large amount of data to identify patterns and markers that are features of specific rare diseases. The use of AI in biomarker discovery enhances precision medicine by uncovering biomarker signatures that are necessary for early detection and treatment of diseases within vast and diverse datasets.
• AI in diagnosis: AI improves diagnosis accuracy by detecting fine patterns in medical images, predicting disease progression, and cross-referencing patient symptoms with large databases of clinical cases, allowing doctors to identify conditions earlier and more reliably.
• AI in the detection of rare diseases: An AI tool used mechanistic insights into genetic diseases to identify treatment options to allow precision medicine for rare diseases.
• AI in cancer treatment: AI can be trained to scan imaging, such as MRIs, to identify and flag potential tumor-like structures in patients' scans with incredible efficiency.

Industry Leader Announcements

• Sudhir Hasbe, Chief Product Officer at Neo4i.

Sudhir Hasbe, Chief Product Officer at Neo4i, commented, “We are thrilled to expand our partnership with QIAGEN Digital Insights, which has been at the forefront of using graph technology within life sciences. As we develop new ways to enhance and integrate the QIAGEN biomedical knowledge graph, we are confident that we will unlock new possibilities for biopharma companies, driving innovation and enhancing patient outcomes.”

• Aiden Synnott, PhD, Corporate Vice President, Global Discovery Services at Charles River

Aiden Synnott, PhD, Corporate Vice President, Global Discovery Services at Charles River, said, “Being a part of DanubeNeuro and collaborating with CEBINA aligns perfectly with our commitment to advancing scientific research and innovation.” “We are eager to contribute our expertise to this acceleration program and support the next generation of breakthroughs in neuroscience.”

Geographical Insights

North America

North America dominated the global rare biomarkers specimen collection and stabilization market in 2024. Ongoing innovations in biomarker research are leading to the development of new biomarkers associated with many diseases.

United States:

According to a report published in October 2024 by the Centers for Disease Control and Prevention, heart disease is the main cause of death for men, women, and people of most racial and ethnic groups in the United States.

• One person dies every 33 seconds from cardiovascular disease.
• 702880 people died from heart disease in 2022. That is the equivalent of 1 in every 5 deaths.

Asia Pacific

Asia Pacific is anticipated to grow at the fastest rate during the forecast period. Rising research and development activities and advanced technologies are driving the growth of the rare biomarkers specimen collection and stabilization market.

• India is facing an increased threat of adult chronic diseases. So, robust biomarkers for cardiovascular diseases and diabetes need to be developed.
• In March 2025, free lung NGS biomarker testing for lung cancer patients in India was launched by the LuNGS Alliance. This initiative is driven by Cancer Research and Statistics Foundation (CRSF) and supported by Pfizer, AstraZeneca, Roche, and lab partner 4basecare, and aims to drive awareness about precision oncology.

Recent Developments

• In April 2025, QIAprep& Plasmodium Kit to Strengthen Malaria Research and Surveillance Efforts was launched by QIAGEN. Malaria remains a major global health threat, with more than 250 million cases and 600000 deaths in 2024, more than 90% of them in Africa.
• In April 2025, the grand opening of the Advanced Therapies Collaboration Centre (AT×CC) in Carlsbad, California, was announced by the world leader in serving science, Thermo Fischer Scientific Inc. This advanced facility is designed to improve the development and commercialization of cell therapies, specifically by supporting biotech, biopharma, and translational customers developing cell-based immunotherapies.

Competitive Landscape

The rare biomarkers specimen collection and stabilization market is highly competitive, with leading pharmaceutical companies like Charles River Laboratories and Thermo Fischer Scientific Inc. holding the highest market share.

The market is dominated by many pharmaceutical companies for their significant contributions to disease diagnosis and treatment. Based on the recent data, the top three companies leading are

• Company Name: Charles River Laboratories
• Year of Incorporation: 1947
• Headquarters: Wilmington, Massachusetts, United States

The revenue was $4.13 billion, representing a 3.9% increase over the previous year 2023 on a reported basis of Charles River Laboratories.

• Company Name: Thermo Fischer Scientific, Inc.
• Year of Incorporation: 2006
• Headquarters: Waltham, Massachusetts, United States

Thermo Fischer Scientific, Inc., the revenue was $32.22 billion in 2020 and $42.88 billion in 2024 on a reported basis.